(R)-2,6-Dioxohexahydropyrimidine-4-carboxylic acid is a chiral heterocyclic compound featuring a hydropyrimidine ring fused with a carboxylic acid group. It is structurally related to orotic acid (vitamin B13) and serves as a key chiral building block in organic synthesis, particularly for the preparation of pharmaceuticals. Its primary application is as a crucial intermediate in the synthesis of various bioactive molecules. Most notably, it is a key precursor in the production of (R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoic acid, which is a critical intermediate for the synthesis of the antidiabetic drug Sitagliptin (Januvia®). The chiral center and the reactive functional groups (carboxylic acid and cyclic urea moiety) make it valuable for constructing complex molecular architectures with specific stereochemistry required in drug development. This compound is typically handled as a high-purity solid for research and manufacturing purposes. Its synthesis and use are of significant interest in process chemistry for the efficient and stereoselective production of active pharmaceutical ingredients (APIs).